Top 5 Stocks to Buy Now
→ Sell Tesla, Buy the New King of FSD Cars (From Chaikin Analytics) (Ad)tc pixel
NASDAQ:HCM

HUTCHMED 6/25/2026 Earnings Report

HUTCHMED logo
$10.29 +0.02 (+0.19%)
Closing price 06/25/2026 04:00 PM Eastern
Extended Trading
$10.20 -0.09 (-0.86%)
As of 07:08 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
ProfileEarnings HistoryForecast

HUTCHMED EPS Results

Actual EPS
N/A
Consensus EPS
-$0.36
Beat/Miss
N/A
One Year Ago EPS
N/A

HUTCHMED Revenue Results

Actual Revenue
N/A
Expected Revenue
$80.92 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

HUTCHMED Announcement Details

Quarter
Date
6/25/2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

HUTCHMED Earnings Headlines

HUTCHMED's experimental drug shows durable responses in advanced bile duct cancer trial
June 25 at 2:08 PM  |  msn.comhttps://www.msn.com/en-us/health/other/hutchmeds-experimental-drug-shows-durable-responses-in-advanced-bile-duct-cancer-trial/ar-AA26xHm7
Syndio Acquires Embrace.ai
June 23 at 12:30 PM  |  businesswire.comhttps://www.businesswire.com/news/home/20260623406678/en/syndio-acquires-embrace.ai/
Sell Tesla, Buy the New King of FSD Cars
In 2023, Marc Chaikin's system flagged an automotive stock as bearish - and it fell 35% shortly after. Today, that same stock has earned a 'Very Bullish' rating after forming a major partnership with Nvidia to power AI-driven autonomous vehicles. This barely-known company was selected to handle the complex job of getting Nvidia's self-driving AI safely inside vehicles - positioning it at the center of a massive trend most investors are still missing through Tesla.tc pixel
June 26 at 1:00 AM  |  Chaikin Analytics (Ad)
isolved Introduces Autonomous AI Agents Built to Own HR Outcomes — Brings Unified HCM Platform to Anthropic's Claude Connectors Directory
June 16, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312891/0/en/isolved-Introduces-Autonomous-AI-Agents-Built-to-Own-HR-Outcomes-Brings-Unified-HCM-Platform-to-Anthropic-s-Claude-Connectors-Directory.html
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM)
June 16, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/edgewise-therapeutics-announces-positive-top-line-data-from-12-week-phase-2-cirrus-hcm-trial-with-edg-7500-in-obstructive-and-nonobstructive-hypertrophic-cardiomyopathy-hcm-302801108.html
isolved Honors Top-Performing Partners at Annual Connect for Partners Event
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/16/3312225/0/en/isolved-honors-top-performing-partners-at-annual-connect-for-partners-event.html
See More HUTCHMED Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like HUTCHMED? Sign up for Earnings360's daily newsletter to receive timely earnings updates on HUTCHMED and other key companies, straight to your email.

About HUTCHMED

HUTCHMED (NASDAQ:HCM) (NASDAQ: HCM) is a fully integrated biopharmaceutical company focused on discovering, developing, manufacturing and commercializing targeted therapies and immunotherapies for the treatment of cancer and other diseases. The company leverages in-house capabilities in small-molecule chemistry, biologics engineering and translational medicine to advance candidates through all stages of development. HUTCHMED’s integrated model encompasses early discovery research, clinical development, regulatory filings and commercial launches, enabling seamless progression from laboratory to market.

HUTCHMED’s commercial portfolio includes several in-market oncology therapies approved in China, including fruquintinib for metastatic colorectal cancer, surufatinib for neuroendocrine tumors and savolitinib for non-small cell lung cancer. Its clinical pipeline features both small molecules and monoclonal antibodies targeting receptor tyrosine kinases, immuno-oncology checkpoints and novel pathways, with ongoing trials in the United States, Europe and Asia. The company has established strategic partnerships and licensing collaborations with leading global pharmaceutical and biotechnology firms to co-develop and co-commercialize its assets.

Founded in 2000 as Hutchison MediPharma and rebranded as HUTCHMED in 2018, the company is headquartered in Hong Kong, with research and development centers in Shanghai and Suzhou, China. HUTCHMED maintains commercial operations across mainland China and extends its clinical research infrastructure to the United States and Europe. Guided by an experienced leadership team with backgrounds in drug discovery, clinical development and commercial strategy, HUTCHMED continues to pursue its goal of delivering innovative medicines to patients worldwide.

View HUTCHMED Profile
Earnings Tools